CNBC
Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC
EconomyDaily Composite
Analysts see the biotech company as a prime takeover target and several pharma giants have been rumored as potential buyers.
C
Source
CNBC
Read full article at CNBC
Opens original article in a new tab
Advertisement